Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

ClinicalTrials.gov ID: NCT01053936

Public ClinicalTrials.gov record NCT01053936. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Open-Label, Randomized, Parallel Group, Dose-Ranging, Pharmacodynamic Phase II Trial to Determine the Effects of Bardoxolone Methyl (RTA 402, Amorphous Dispersion) on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease (eGFR 15-45 mL/Min/1.73m2)

Study identification

NCT ID: NCT01053936
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Biogen; Industry
Enrollment: 129 participants

Conditions and interventions

Conditions

Interventions

Bardoxolone methyl (amorphous dispersion) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 30, 2010
Primary completion: Dec 30, 2010
Completion: Feb 27, 2011
Last update posted: May 28, 2025

2010 – 2011

United States locations

U.S. sites: 26
U.S. states: 14
U.S. cities: 26

Facility	City	State	ZIP	Site status
Not listed	Montgomery	Alabama	36106	—
Not listed	Phoenix	Arizona	85012	—
Not listed	Tempe	Arizona	85284	—
Not listed	La Mesa	California	91942	—
Not listed	Riverside	California	92505	—
Not listed	San Dimas	California	91773	—
Not listed	Washington D.C.	District of Columbia	20036	—
Not listed	Brandon	Florida	33511	—
Not listed	Port Charlotte	Florida	33952	—
Not listed	West Palm Beach	Florida	33401	—
Not listed	Augusta	Georgia	30901	—
Not listed	Canton	Georgia	30114	—
Not listed	Chicago	Illinois	60616	—
Not listed	Peoria	Illinois	61603	—
Not listed	Brooklyn Center	Minnesota	55430	—
Not listed	Morehead City	North Carolina	28557	—
Not listed	Winston-Salem	North Carolina	27103	—
Not listed	Pittsburgh	Pennsylvania	15224	—
Not listed	Providence	Rhode Island	02904	—
Not listed	Chattanooga	Tennessee	37304	—
Not listed	Corpus Christi	Texas	78404	—
Not listed	Dallas	Texas	75390	—
Not listed	Greenville	Texas	75402	—
Not listed	Houston	Texas	77099	—
Not listed	San Antonio	Texas	78215	—
Not listed	Federal Way	Washington	98003	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01053936, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 28, 2025 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01053936 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →